Investors Forum |
A community of New Zealand investors |
|
|
#1 (permalink) |
|
Senior Member
Join Date: Dec 2006
Posts: 35,579
|
SYDNEY - Neuren Pharmaceuticals has successfully completed a safety and tolerability trial of its traumatic brain injury drug NNZ-2566.Chief executive David Clarke said the trial on healthy volunteers was conformation that NNZ-2566...
More... |
|
|
|